Analyst Jason Zemansky of Bank of America Securities maintained a Buy rating on Insmed (INSM – Research Report), retaining the price target of $40.00.
Jason Zemansky has given his Buy rating due to a combination of factors surrounding Insmed’s promising pipeline and potential market opportunities. The company’s late-stage assets, including brensocatib, TPIP, and Arikayce, are poised for significant developments that could transform Insmed’s financial outlook. Zemansky acknowledges market concerns, particularly regarding brensocatib’s ASPEN trial, but remains optimistic about the drug’s prospects and the company’s strategy to navigate regulatory pathways. He suggests that the stock’s year-to-date underperformance does not reflect the company’s potential and believes that the favorable risk/reward profile justifies a Buy rating with a $40 price objective.
Furthermore, Zemansky emphasizes the strength of Insmed’s pipeline, noting the versatility and potential superiority of TPIP over standard of care treatments for pulmonary arterial hypertension. He also points out the significant market expansion opportunity for Arikayce in the first-line treatment of a patient population that is substantially larger than the current refractory setting. Despite existing competition, Zemansky expresses confidence in Insmed’s competitive positioning and their ability to capitalize on these near-term catalysts, underpinning his positive stance on the stock.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $52.00 price target.
Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of INSM in relation to earlier this year.
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Insmed (INSM) Company Description:
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Read More on INSM:
